Fresenius Medical Care AG & Co. KGaA initiates firm plans for change of the legal form into a German stock corporation

Fresenius Medical Care AG & Co. KGaA / Key word(s): Strategic Company Decision Fresenius Medical Care AG & Co. KGaA initiates firm plans for change of the legal form into a German stock corporation 21-Feb-2023 / 19:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Bad Homburg, 21 February 2023. The Supervisory Board of Fresenius Medical Care Management AG has today approved the Management Board’s resolution to initiate firm plans for a change of the legal form of Fresenius Medical Care AG & Co. KGaA (the "Company") from a partnership limited by shares (Kommanditgesellgesellschaft auf Aktien – KGaA) into a German stock corporation (Aktiengesellschaft – AG). The Supervisory Board of Fresenius Medical Care AG & Co. KGaA has taken note with approval of the resolutions mentioned before. It is intended to convene an extraordinary general meeting of the Company at the beginning of the third quarter 2023 which shall resolve on the change of the legal form. Thereby, the Management Board and the Supervisory Board of Fresenius Medical Care Management AG as well as the Supervisory Board of Fresenius Medical Care AG & Co. KGaA support the intention of Fresenius SE & Co. KGaA to seek the deconsolidation of the Company. Under the U.S. Securities Act of 1933, as amended (the “Securities Act”), this ad hoc announcement may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA (“FME”). FME intends to file a registration statement on Form F-4 under the Securities Act with the U.S. Securities and Exchange Commission (the “SEC”), including an information statement/prospectus constituting a part thereof. FME SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC, INCLUDING THE INFORMATION STATEMENT/PROSPECTUS THAT WILL BE PART OF THE REGISTRATION STATEMENT, AS THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED CONVERSION. The final information statement/prospectus will be distributed to FME shareholders. Shareholders may obtain a free copy of the disclosure documents (when they are available) and other documents filed by FME with the SEC at the SEC’s website at www.sec.gov or from Fresenius Medical Care AG & Co. KGaA, Attention: Investor Relations, Else-Kröner-Strasse 1, 61352 Bad Homburg v.d.H., Germany. Contact: Dr. Dominik Heger EVP | Head of Investor Relations, Strategic Development & Communications dominik.heger@fmc-ag.com P. +49 6172 609 2601 21-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	Fresenius Medical Care AG & Co. KGaA
	Else-Kröner-Straße 1
	61352 Bad Homburg
	Germany
Phone:	+49 (0) 6172- 609 2525
Fax:	+49 (0) 6172- 609 2301
E-mail:	ir@fmc-ag.com
Internet:	www.freseniusmedicalcare.com
ISIN:	DE0005785802
WKN:	578580
Indices:	DAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID:	1564841

End of Announcement	EQS News Service

show this